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METHOD OF DETECTING SINGLE 
NUCLEOTIDE POLYMORPHISMS 
BACKGROUND OF THE INVENTION 
Single nucleotide polymorphisms (SNPs) are DNA 
sequence variations that occur when a single nucleotide (A, T, 
2 
(1) a nucleic acid amplification step, and (2) a SNP genotyp-
ing step. In some aspects, the sequences contain one or more 
single nucleotide polymorphisms (SNPs ). 
In some aspects, the disclosure provides a method of 
detecting sequences comprising (1) a nucleic acid amplifica-
tion step that is substantially isothermal, and (2) a SNP geno-
typing step that uses one or more binary pro bes. In a preferred 
embodiment, the nucleic acid amplification uses specific 
primers and the isothermal temperature is room temperature. 
C, or G) in the genome sequence is altered. For example, a 
SNP might change the DNA sequenceAAGGCTAA to ATG-
GCTAA. For a variation to be considered a SNP, it gener-
ally-but not always--occurs in at least 1 % of the population. 
SNPs make up -90% of all human genetic variation, and 
occur every 100 to 300 bases along the 3-billion-base human 
genome. SNPs can occur in coding (gene) and noncoding 
regions of the genome. Many SNPs have no effect on cell 
function, but others have been associated with inherited traits, 
genetic diseases, age-associated diseases, and responses to 
drugs and environmental factors. 
10 In some embodiments, the specific primers and/or binary 
probes are designed for room-temperature (e.g. 20-25° C.) 
hybridization, e.g., primers and/or analyte-binding arms with 
lengths from about 7 nucleotides to about 12 nucleotides. In 
other embodiments, the binary probe is a binary DNA per-
15 oxidase probe. 
In some aspects, the disclosure provides a sequence-detect-
ing kit comprising (1) one or more reagents needed for a 
nucleic acid amplification step, and (2) one or more reagents 
needed for a SNP genotyping step. In other aspects, the dis-
SNP genotyping assays are genetic tests that determine the 
presence of a sequence in nucleic acid, which can be used to 
detect the presence ofSNPs -or other sequence variations in 
nucleic acids, e.g., microsattelites, deletions and insertions, 
duplications, and translocations. SNP genotyping assays can 
20 closure provides a sequence-detecting apparatus comprising 
(1) functionality for conducting a nucleic acid amplification 
step, and (2) a SNP genotyping step. 
be separated into two groups based on mechanisms: (1) 
primer extension assays (including sequencing and PCR), 
and (2) hybridization assays (e.g., molecular beacons, 25 
microarrays, oligonucleotide ligation, and allele-specific 
endonuclease cleavage (e.g., invader assay)). Many assays 
require input of nucleic acid at quantities greater than typical 
yields of nucleic acid isolation procedures, and necessitate a 
nucleic acid amplification step to amplify nucleic acids in 
sufficient quantity to be detectable by the assay. The nucleic 30 
acid amplification steps use (1) sequence-specific primers to 
amplify regions of interest of nucleic acid (e.g. containing a 
SNP), and (2) high hybridization temperatures, necessary for 
sequence-specific primers to specifically hybridized and 
amplify template nucleic acid, which leads to specific ampli- 35 
fication. In absence of high hybridization temperatures, the 
yield of amplified product drops and disappears from electro-
phoretic gels, and multiple background products appear 
(Henegariu, et. al., Biotechniques, 23:504 (1997)). 
Nucleic acid amplification can be (1) thermocycling, e.g. 40 
PCR, using multiple heating cycles of94° C., 55° C., and 72° 
C. for template denaturation, primer hybridization, and 
primer extension, respectively; or (2) isothermal, e.g., per-
formed substantially at a single temperature, e.g. employing 
different mechanisms to bypass the denaturation step, and 45 
using single heating cycles of 37° C.-to-55° C. for primer 
hybridization and primer extension. Examples of isothermal 
amplification--capable of amplifying naturally occurring 
DNA or RNA-include Q~ replicase (Tyagi et al., PNAS 
USA 93:5395, 1996); self-sustained sequence replication, 50 
3SR (Guatelli et al., PNAS USA 87:1874, 1990); strand dis-
placement amplification, SDA (Walker et al., PNAS USA 
89:392, 1992); and helicase dependent amplification (U.S. 
application Ser. No. 10/665,633). SNP genotyping assays 
requiring nucleic acid amplification-and its use of high 55 
hybridization temperatures-are not ideal for use in diagnos-
tic assays, especially in kits and apparatuses in Point-of-Care 
(POC) settings and patient use. Towards fulfilling this need, a 
new combination of SNP genotyping assay and nucleic acid 
amplification was developed-whose nucleic acid amplifica- 60 
tion step can use heating cycles of less than 37° C., for 
example, room temperature. 
SUMMARY OF THE INVENTION 
DETAILED DESCRIPTION OF THE INVENTION 
Overview 
The disclosure features a novel method and reagents for 
detecting sequences (e.g. SNPs or other sequence variations) 
in nucleic acid comprising (1) a nucleic acid amplification 
step, and (2) a SNP genotyping step. Described herein are kits 
and apparatuses designed for executing the nucleic acid 
amplification step and the SNP genotyping step. 
It has been found that several colormetric SNP genotyping 
assays have template nucleic acid detection limits of 1 nM to 
1 mM, corresponding to 6xl09 to 6xl012 molecules for a 10 
µl reaction. This number of required molecules is greater than 
the number of molecules yielded from typical DNA harvests 
from saliva (3xl07 molecules -110 µg gDNA/2 mLs) and 
blood (lxl08 molecules -370 µg gDNA/10 mLs). To make 
SNP genotyping assays and colormetric SNP genotyping 
assays compatible with typical DNA harvest methods used in 
genetic testing, a step was developed involving a nucleic acid 
amplification step to amplify the template DNA. It was found 
that SNP genotyping assays--e.g. binary probes-can be 
used to detect sequences in nucleic acid that was specifically 
amplified-e.g. by using specific primers-under conditions 
of reduced primer specificity-e.g. low hybridization tem-
peratures. The has been found that such use of specific prim-
ers and reduced specificity conditions provides (1) greater 
enrichment of the specific fragment containing the sequence 
or SNP than use of non-specific primers, and (2) greater 
convenience than use of high hybridization temperatures 
which require heating apparatuses (e.g. incubator or heater or 
thermal cycler). 
It has also been found that for nucleic acids that are less 
heterogenous than human cell genomic DNA--e.g, genomic 
DNA from organisms with smaller genomes than humans 
(e.g. viruses); e.g., genomic DNA from human cells that has 
been fractionated-one can use specific primers that are 
shorter than those used in traditional nucleic acid amplifica-
tion methods, e.g. primers less than 18 nucleotides, e.g. prim-
ers designed for room-temperature (e.g. 20-25° C.) hybrid-
izations, e.g. primers from about 7 nucleotides to about 12 
nucleotides. Also, it has been found that for analytes that are 
The present invention describes a method and reagents for 
detecting sequences in nucleic acid, the method comprising 
65 amplified nucleic acids (e.g. a specific fragment of nucleic 
acid amplified by at least 200-fold), one can use binary probes 
with analyte-binding arms that are shorter than those used in 
US 9,121,053 B2 
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traditional SNP genotyping assays, e.g. arms designed for 
room-temperature (e.g. 20-25° C.) hybridizations, e.g. arms 
from about 7 nucleotides to about 12 nucleotides. 
Thus, one unique feature of the present invention is use of 
a SNP genotyping assay in combination with nucleic acid 
amplification that optionally uses hybridization temperatures 
less than 37° C. As SNP genotyping assays can also be per-
formed at room temperature, the present invention provides a 
generalized sequence or SNP detection method that can be 
performed at room temperature. The produced signal is a 
visually detectable color change. Together, these advantages 
make the method ideal for kits and apparatuses for POC 
diagnostics. 
Nucleic Acid Amplification 
In one embodiment, the nucleic acid amplification step 
involves the amplification (e.g. synthesis) of nucleic acid (or 
region thereof), also referred herein as template nucleic acid, 
by a RNA or DNA polymerase. In some aspects, the poly-
merase is mesophilic (e.g. E.coli DNA Polymerase I, Kienow 
Fragment, phi29 DNA Polymerase, T4 DNA Polymerase, 
Reverse Transcriptase). In other aspects, the polymerase is 
thermophilic (Taq) or psychrophilic (e.g. pike lymphosar-
coma DNA polymerase (Papas et al., Cancer Research 
37:3214 1977)), preferentially with activity at room-tempera-
ture (e.g. 20-25° C.). 
In some aspects, the template nucleic acid is DNA or RNA. 
In other aspects, the template nucleic acid is naturally occur-
ring or artificial. In some embodiments, the RNA is messen-
ger RNA, ribosomal RNA, transfer RNA, small nuclear RNA, 
small nucleolar RNA, microRNA, or XIST RNA. In other 
embodiments, the DNA is genomic DNA (gDNA), episomal 
DNA, or mitochondrial DNA. 
In some embodiments, the nucleic acid amplification step 
involves addition of other enzymes, for example, helicases, 
primases, and single-strand binding proteins, which can 
result in amplification of the template nucleic acid of at least 
3-fold to greater than 1 million-fold. 
In some embodiments, the nucleic acid amplification step 
includes other reagents to enhance amplification carried out 
4 
In some aspects, the primers are specific primers, which are 
complementary to certain regions of the template, and the 
region of the template that is amplified is defined by the 
primers utilized. In one embodiment, primer hybridization is 
performed at temperatures of 50° C.-to-65° C., e.g., 3-5° C. 
below the melting temperature of primers of 18-to-30 nucle-
otides. In a preferred embodiment, primer hybridization is 
performed at temperatures less than 37° C., more preferably 
at room temperature, and more preferably at 20-to-25° C. In 
1 o another embodiment, the primers include random primers-a 
mixture of primers of many or all possible sequences, and all 
regions of the template are generally amplified by use of these 
primers (e.g. random hexamers)--e.g., use of random prim-
ers and one or more specific primers. In a preferred embodi-
15 ment, the nucleic acid amplification is performed using iso-
thermal conditions, i.e., heating cycle at (predominantly) one 
temperature, e.g. one temperature for primer hybridization 
and extension, e.g. 37° C.-to-65° C. Preferably the tempera-
ture for isothermal conditions is less than 37° C., more pref-
20 erably the temperature is room temperature, and more pref-
erably the temperature is 20-to-25° C. 
In one embodiment, the nucleic acid amplification is a 
known nucleic acid amplification method performed using 
isothermal conditions; preferably the temperature for isother-
25 ma! conditions is less than 37° C., more preferably the tem-
perature is room temperature, and more preferably the tem-
perature is 20-to-25° C. In a preferred embodiment, the 
known nucleic acid amplification method uses isothermal 
conditions and one or more specific primers (which are 
30 complementary to certain regions of the template, and the 
region of the template that is amplified is defined by the 
primer(s) utilized. Examples of known nucleic amplification 
methods include whole genome amplification (Lasken and 
Egholm, Trends in Biotech 21: 531, 2003 ), for example, mul-
35 tiple displacement amplification (MDA) (using phi29 DNA 
polymerase) (Dean et al. PNAS 99:5261, 2002) and the 
p WGA platform (using the 63-kDa T7 gene 4 protein encod-
ing a helicase/primase complex) of Biohelix (Beverly, 
Mass.). Other examples include Q~ replicase (Tyagi et al., 
40 PNAS USA 93: 539 5, 1996); self-sustained sequence replica-
tion, 3SR (Guatelli et al., PNAS USA 87:1874, 1990); strand 
displacement amplification, SDA (Walker et al., PNAS USA 
89:392, 1992); and helicase dependent amplification, HDA 
by the RNA or DNA polymerase, or by other enzymes (e.g., 
helicases, primases, single-strand binding proteins). The 
reagents include one or more of nucleoside diphosphoki-
nases, inorganic pyrophosphatases, an ATP regeneration sys-
tem (e.g., combination of creatine kinase and phosphocreat- 45 
ine), a 5'-to-3' exonuclease (e.g., bacteriophage T7 gene 6 
exonuclease ), ligase (e.g., bacteriophage T7 DNA ligase ), 
potassium glutamate, DMSO, and dextran polymer. 
(U.S. application Ser. No. 10/665,633). 
In a preferred embodiment, the nucleic acid amplification 
using isothermal conditions amplifies a specific fragment of 
the template nucleic acid by use of specific primers and low 
hybridization temperature, e.g., less than 37° C., e.g., room 
temperature, e.g., 20-to-25° C. It has been found that nucleic In some aspects, the nucleic acid amplification steps 
involve the addition of one or more oligonucleotide primers. 
Primers are utilized by polymerases to initiate DNA synthe-
sis, are small nucleic acid molecules generally 18-to-30 bases 
50 acid amplification using low hybridization temperatures (25° 
C.) amplifies the specific fragment of template nucleic acid, 
e.g., by at least 200-fold. 
In another embodiment, the nucleic acid amplification step 
is carried out in a solid matrix, such as agarose or polyacry-
55 !amide (Mitra and Church, Nucleic Acids Research 27:e34, 
1999). 
in length, and are designed using known strategies (e.g., see 
Qiagen guidelines (Hilden, Germany), e.g. Qiagen News 5: 1 
1997). The primers can be DNA, RNA, or PNA, and are 
normally synthesized by chemical methods. The primers can 
also include nucleotide analogs or modified nucleotides (e.g. 
WIPO Standard ST.25 (2009), Appendix 2, WO 92/20823), 
e.g., having altered base or sugar, e.g., to substitute for a 
normal nucleotide in the primer or to impart a particular 
feature (e.g., increased stability or for detection). In other 
embodiments, the nucleic acid amplification step involves 
addition of reagents in place of, or addition to, the oligonucle-
otide primers, for example, primases and optionally heli-
cases, for example, the gene 4 protein of bacteriophage T7, 65 
e.g., the 63-kDa T7 gene 4 protein that encodes the helicase/ 
primase complex (Biohelix, Beverly, Mass.). 
In some aspects, the enzymes of the nucleic acid amplifi-
cation are treated-prior to inclusion in the reaction mix-
ture-with UV irradiation to reduce the amplification of con-
60 taminating DNA in the enzyme preparations. Preferably the 
ultraviolet light dose is 10 to 1000 µW/cm 2 for 15 sec to 15 
mm. 
Amplification of the template nucleic acid is such that the 
amount of amplified product is preferably at least about 
3-fold amplified, more preferably the amplified product is 
100-fold greater, or at least 1000-fold greater, or at least 
10,000-fold greater, or at least 100,000-fold greater, or at least 
US 9,121,053 B2 
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1,000,000-fold greater, or at least 10,000,000-fold greater or 
even more than the DNA put into the reaction mixture. 
In some aspects, the nucleic acid amplification step 
includes ATP and CTP in addition to the 4 dNTPs. 
A preferred source of template nucleic acid to be amplified 
is lysed human cells and the template nucleic acid is gDNA. 
Preferably, the added gDNA template is 1 µg or less, and the 
reaction mixture is 10 to 200 µ!. In some embodiments, the 
human cells are isolated from sources used in genetic testing, 
for example, buccal cells, blood, bone, ear (e.g. wax), hair 
(e.g. with root), nails, nasal secretion, saliva, sperm, skin, 
teeth, and tissue. In some embodiments, the human cells are 
fetal cells isolated from sources used in pre-natal genetic 
testing, for example, anmiotic fluid, chorionic villus samples 
(CVS), direct fetal sample, maternal blood, placental tissue, 
and umbilical blood samples (PUBS). In some embodiments, 
the humans cells are cells of in vitro fertilization, for example, 
embryos (e.g. pre-implantation), eggs (e.g. oocytes and 
related cells), and sperm. 
6 
vivo) and tissues (in situ) using known methodologies. The 
nucleic acid amplification is performed using purified or at 
least substantially purified proteins. 
SNP Genotyping 
Nucleic acid to be genotype--e.g. contains the sequence or 
SNP to be detected-by SNP genotyping assays is also herein 
referred to as "analyte". 
In one embodiment, the SNP genotyping step involves the 
detection of sequences or SNPs in analytes by a SNP geno-
10 typing assay. In a preferred embodiment, the SNP genotyping 
assay includes one or more binary probes. In some aspects, 
the analyte is template nucleic acid, e.g., DNA or RNA, 
naturally occurring or artificial, e.g., gDNA. In a preferred 
embodiment, the analyte is amplified nucleic acid from a 
15 nucleic acid amplification step. 
Binary probes generally comprise two relatively short oli-
gonucleotides (e.g. 7-10 nucleotides) that hybridize side-by-
side to target sequences in the analyte, and generate a signal 
by different mechanisms (e.g., fluorescence, luminesces-
20 cence, or colormetric). The probes are called "binary" 
because the two parts of the probe act synergistically and the 
detection event occurs only when both parts are hybridized to 
the analyte. The two short oligonucleotides can be two sepa-
Other preferred sources of template nucleic acid to be 
amplified are organisms with genomes that are less heterog-
enous than human cells, e.g., organisms with genomes 
smaller than human cells (3200 million base pairs), e.g., 
organisms with genomes with less non-coding sequences 
(e.g. repeat sequences) than human cells. (Genome size and 25 
non-coding sequences increase sequence heterogeneity, and 
the probability of non-specific nucleic acid amplification). 
Examples of organisms with genomes smaller than human 
cells include insects (100 million-to-500 million base pairs), 
microbes (200,000-to-10 million base pairs), and viruses 
(5000-to-l million base pairs). 
rate molecules, or two parts of a single molecule. 
In one aspect, the SNP genotyping step detects one or more 
sequences in nucleic acid (e.g. the analyte). In one embodi-
ment, the SNP genotyping step is considered highly specific, 
and detects target sequences (one or more) and false positive 
sequences (one or more) at a ratio of 20: 1 or greater. In 
30 another embodiment, the SNP genotyping step is considered 
moderately specific, and detects target sequences and false 
positive sequences at a ratio of <20: 1 to > 1: 1. In some embodiments, the nucleic acid amplification 
includes a prior template nucleic acid enrichment step (to 
reduce nucleic acid heterogeneity), where the template 
nucleic acid is positively selected, or other nucleic acid (e.g. 
contaminating) is negatively selected (and thereby enriches 
the specific template nucleic acid). For example, for amplifi-
cation of the human Y chromosome, nucleic acids from 
human cells can be positively selected by use ofY chromo-
some antibodies to isolate Y chromosomes, or negatively 
enriched by use of antibodies against other (non-Y) chromo-
somes to deplete said chromosomes, and enrich for Y chro-
mosomes. In other aspects, the nucleic acid amplification of 
template nucleic acid involves the addition of one or more 
oligonucleotide primers that are less than 18 nucleotides in 
length, e.g., primers with room temperature (e.g. 20-25° C.) 
hybridization temperatures, e.g., primers from about 7 nucle-
otides (e.g. poly G) to about 12 nucleotides (e.g. poly A) in 
length. In a preferred embodiment, the template nucleic acid 
(to be amplified) is less heterogenous than human cell 
genomic DNA, e.g., nucleic acid from (a) organisms with 
genomes smaller than human cells; (b) organisms with 
genomes with less non-coding sequences than human cells; 
or (c) human cells (e.g. genomic DNA) that have been sub-
jected to prior template nucleic acid enrichment steps. For 
example, for viruses with 5000 base pair genomes, one can 
use primers of 8 nucleotides (which should hybridize to 
sequences randomly occurring at a frequency of 1 :65,000 
( 48 )); and for example, for viruses with 1 million base pair 
genomes, one can use primers of 12 nucleotides (which 
should hybridize to sequences randomly occurring at a fre-
quency ofl: 16 million (4 12)). Cells or viruses can be lysed to 
form a lysate, which is added to the nucleic acid amplification 
reaction mixture. Lysis can be carried out by any method 
known in the art, such as use oflysozyme or detergents. 
The nucleic acid amplification step is generally carried out 
"in vitro", but can be adapted to be carried out in cells (in 
In one embodiment, the SNP genotyping step detects one 
or more sequences (in nucleic acid) containing single nucle-
35 otide polymorphisms (e.g. that may or may not be present in 
a reference sequence, e.g. wildtype sequence). In a second 
embodiment, the SNP genotyping step detects one or more 
sequences containing single nucleotide mutations, additions, 
deletions, or substitutions (e.g. that may or may not be present 
40 in a reference sequence). In a third embodiment, the SNP 
genotyping step detects sequences containing larger poly-
morphisms, mutations, additions, deletions, duplications, and 
substitutions, for example, involving two, three, or more 
nucleotides. Mutations includes missense mutations, non-
45 sense mutations, silent mutations, and splice-site mutations. 
In some aspects, the binary probes are binary fluorimetric 
probes, e.g., two oligonucleotides hybridize to target 
sequences in the analyte to generate a fluorescent signal. In 
other aspects, the binary probes are binary luminescence 
50 probes, e.g., two oligonucleotides hybridize to target 
sequences to generate a luminescent signal. In other aspects, 
the binary probes are binary colormetric probes, e.g., two 
oligonucleotides hybridize to target sequences to generate a 
colormetric signal (e.g. visible color). Examples of binary 
55 probes include Xu eta!., Nat. Biotech. 19:148, 2001; Sando et 
al., JACS 126:1081, 2004; Bichenkova et al., Biochem. Bio-
phys. Res. Commun., 332:956, 2005; Kolpashchikov, JACS 
127:12442, 2005; Kolpashchikov, JACS, 128:10625, 2006; 
Marti et al., J. Nucleic Acids Res., 34:3161, 2006; Kitamura 
60 eta!., Anal. Biochem. 359:259, 2006; Kolpashchikov, Chem-
BioChem., 8:2039, 2007. 
In a preferred embodiment, the binary probe is a binary 
colometric probe, e.g., a binary enzyme probe, e.g, a binary 
DNA peroxidase probe. (Kolpashchikov, JACS, 130:2934, 
65 2008). In general, binary DNA peroxidase probes-upon 
binding target sequences in the analyte-form a guanine-
quadruplex (G-quadruplex) that is capable of binding hemin. 
US 9,121,053 B2 
7 
G-quadruplex-bound hemin demonstrates hydrogen peroxi-
dase-like activity that is -250 times greater than free (un-
bound) hemin (Li et al., Biochem. 35:6911, 1996; Travascio 
et al., Chem. Biol. 5:505, 1998; Travascio et al., Chem. Biol. 
6:779, 1999). The complex of binary DNA peroxidase probe 5 
and hemin can catalyze oxidation of various substrates to 
luminescent or colored products, which can be detected spec-
trophotometrically or visually (Xiao et al., JACS, 126; 7430, 
2004; Li et al., Biosens Bioelectron 222:2570, 2007; Pavlov 
eta!., Anal. Chem. 76:2152, 2004;Xiao eta!., Chembiochem. 10 
5:374-379, 2004). 
In one embodiment, binary DNA peroxidase probe com-
prises two oligonucleotide strands, wherein, a first oligo-
nucleotide strand comprises: 
a) an analyte binding arm at the 5'-terminus, which is 15 
complementary to and hybridizes to a first region of the 
analyte, 
b) an optional linker, and 
c) a porphyrin binding arm at the 3'-terminus, 
8 
perature (e.g. 20-25° C.) hybridization, e.g., the analyte-bind-
ing arms are from about 7 nucleotides to about 12 nucleotides. 
In another aspect, for binding of analytes that are less 
heterogenous than human genomic DNA, the analyte-binding 
arm has a length that, with the second analyte-binding arm, 
permit the binary probe to hybridize to analytes at tempera-
tures less than 3 7° C., more preferably room temperature, and 
more preferably between 20-to-25° C. Here, binary probe 
hybridization temperature, and the corresponding length (and 
sequence) of the analyte-binding arm, are determined experi-
mentally using methods known in the art. 
In some aspects, the analyte-binding arms have structure 
stabilization arms (SSA) for added sensitivity-which are 
additional nucleotide sequences (up to 40, preferably 3-10) 
added to the free end of the analyte binding arms that are 
complementary to and hybridize with an internal region of the 
analyte-binding arm to form a stem-loop structure. 
In some aspects, the binary DNA peroxidase probe hybrid-
izes to an analyte, enabling its G-quadruplex to noncovalently 
and a second oligonucleotide strand comprises: 
a) a porphyrin binding arm at the 5'-terminus, 
b) an optional linker, and 
c) an analyte binding arm at the 3'-terminus, which is 
complementary to and hybridizes to a first region of the 
analyte. 
20 bind hemin by way of stacking and hydrophobic interactions, 
to form an enzyme-like molecule with hydrogen peroxidase-
like activity. In other aspects, a more sensitive binary DNA 
peroxidase probe with a G-quadruplex covalently bound to 
hemin (via one or both of the antiparallel oligonucleotides), 
The oligonucleotide strands can be DNA, RNA, PNA, LNA, 
or combination of thereof and can include nucleotide analogs 
25 hybridizes to an analyte to form an enzyme-like molecule 
with hydrogen peroxidase-like activity. 
or modified nucleotides (e.g. WIPO Standard ST.25 (2009), 
Appendix 2, WO 92/20823 ), e.g. having altered base or sugar. 
In a preferred embodiment, the porphyrin is hemin (trade 30 
name Panhematin), and the binding arms for hemin are DNA. 
In a second preferred embodiment, the binding arms for DNA 
analytes are DNA, for DNA-DNA duplexes are less stable 
than RNA-DNA duplexes, and therefore, more sensitive to 
nucleotide base pair mismatches, which improves their abil- 35 
ity to detect SNPs. 
In some aspects, the analyte- and porphyrin-binding arms 
are optionally connected to each other by linker molecules 
(which increase flexibility between the analyte- and hemin-
binding arms of each probe strand permitting formation of a 40 
four-way junction with the analyte. The linker is not required 
if there is enough flexibility in the hemin- and analyte-binding 
arms of each strand to permit formation of the four-way 
junction with the analyte). In one embodiment, the linker is 
triethylene glycole. In another embodiment, the linker is an 45 
oligonucleotide linker. 
The analyte-binding arms are customized for each particu-
lar analyte. In general, the arms are complementary to a target 
sequence (e.g. containing the SNP) on one strand of the 
template nucleic acid. For optimum selectivity, the analyte- 50 
binding arm of each strand of the probe can be lOOO's of 
nucleotides in length. For binding of human genomic DNA 
analytes, analyte-binding arms are preferably 6-to-20 nucle-
otides, and more preferably about 10 nucleotides (which 
makes the total recognizable analyte fragment about 20 55 
nucleotides, which will cover any unique sequence in the 3 .2 
billion nucleotide human genome (i.e., a 20 nucleotide 
sequence randomly occurs at a frequency of 1: 1099 billion 
( 420 nucleotides). For binding of analytes that are less heter-
ogenous than human genomic DNA-for example, nucleic 60 
acids (a) from organisms with genomes smaller than human 
cells; (b) from organisms with genomes with less non-coding 
sequences than human cells; (c) subjected to prior template 
nucleic acid enrichment, and/or ( d) amplified in nucleic acid 
amplification steps using one or more specific primers (e.g., a 65 
specific fragment of nucleic acid amplified by at least 200-
fold)-the analyte-binding arms are designed for room-tern-
The hemin-binding arms of the G-quadruplex can have 
different configurations. For example, the first hemin-binding 
arm can comprise 5'-gggttggg-3' and the second hemin-bind-
ing can comprise 3'-gggatggg-5'; the first binding arm can 
comprise 5'-gggcgggttggg-3' (SEQ ID NO. 1) and the second 
binding arm 3'-ggg-5'; the first binding arm 5'-ggg-3' and the 
second binding arm 3'-gggcgggatggg-5'(SEQ ID G. 2). 
In some embodiments, the binary probe can be conjugated 
to one or more solid supports, e.g., gold nanoparticles. For 
example, the binary probes can be fixed to the surface of 
different gold nanoparticles, and on addition of template 
DNA, a polymer network forms, which can be detected, e.g., 
red-to-purple color change (Mirkin et al., Chem. Rev. 105: 
1547, 2005; Sato, Anal. Sci., 23:17 2007; Murphy, TheAna-
lyst 129:970 2004). 
The SNP genotyping step is generally carried out "in 
vitro", but can be adapted to be carried out in cells (in vivo) 
and tissues (in situ) using known methodologies. 
Genetic Testing 
In some aspects, the disclosure provides a method of 
detecting sequences or SNPs in humans cells. In other 
aspects, the disclosure provides a method of detecting 
sequences or SNPs in other eukaryotic cells (e.g., non-human 
mammalian cells, plant cells), viruses, and microbial cells 
(e.g., bacterial, yeast). In some embodiments, the method is 
used to detect sequences or SNPs associated with patho-
genecity and drug resistance (e.g. rRNA mutations associated 
with antibiotic resistance in bacteria). In other embodiments, 
the method is used to detect sequences or SNPs associated 
with specific industrial and agriculture applications (e.g. 
mutations associated with a desired genetic modified organ-
ism (GMO) for a particular use, e.g., GMO crop planting). 
In another embodiment, the invention features a method of 
detecting contaminating DNA by detecting the sequences or 
SNPs of the contaminating DNA. Contaminating DNA refers 
to any DNA that may be contaminating a preparation, for 
example, the DNA of an organism used to derived the prepa-
ration, or the DNA of a contaminating organism ( e.g acquired 
during the making of the preparation). 
In some aspects, the DNA is added to a first reaction mix-
ture for the nucleic acid amplification step, and after adequate 
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Cheek swabs from 10 normal patients; 1 cystic fibrosis 
amplification for detection, part or all of the first reaction 
mixture is added to a second reaction mixture for the SNP 
genotyping step. In some embodiments, the first reaction 
mixture is added to the second reaction mixture before 
completion (e.g. adequate amplification) where the nucleic 
acid amplification step continues to completion during the 
SNP genotyping step. In other embodiments, the DNA is 
added to a combination of first reaction mixture and second 
reaction mixture, where the nucleic acid amplification step 
and SNP genotyping step can occur simultaneously, and 
optionally report the amount of amplified DNA containing 
the sequence or SNP in real time, e.g, real-time PCR (Gibson 
et al., Genome Research 6:995, 1996). 
In another aspect, the invention features a kit for detecting 
sequences or SNPs. The kit can be a point-of-care (POC) kit. 
The kit preferably includes components for performing a 
nucleic acid amplification step and a SNP genotyping step. In 
one embodiment, the nucleic acid amplification is carried out 
10 patient homozygous for the G551D mutation (1652G>A) in 
the CFTR gene; and 1 cystic fibrosis patient homozygous for 
the R553X mutation (1657C>T) in the CFTR gene are taken 
with an Easy-Swab and harvested using the BuccalQuick kit 
(TrimGen, Sparks, Md.). Briefly, the swab is washed in Buc-
15 calQuick kit Extraction Buffer, and the resulting DNA-con-
taining buffer is vortexed, heated at 55° C. for 5 minutes and 
90° C. for 3 minutes. The yield of the DNA is l-to-2 µg per 
swab. 
in a first reaction mixture, and the SNP genotyping step is 20 
carried out in a second reaction mixture. In a preferred 
embodiment, the first reaction mixture includes reagents 
needed for nucleic acid amplification under isothermal con-
ditions, and the second reaction mixture includes one or more 
binary probes. Alternatively, the nucleic acid amplification 25 
and SNP gentotyping are carried out in a single reaction 
mixture, e.g., a combination of the first and second reaction 
mixtures. 
In another aspect, the invention features an apparatus for 
detecting sequences or SNPs. The apparatus can be a diag- 30 
nostic or a POC diagnostic. The apparatus preferably involves 
a nucleic acid amplification step and a SNP genotyping step. 
In one embodiment, the nucleic acid amplification is carried 
out in a first reaction mixture, and the SNP genotyping step is 
35 
carried out in a second reaction mixture. In a preferred 
embodiment, the first reaction mixture includes reagents 
needed for nucleic acid amplification under isothermal con-
ditions, and the second reaction mixture includes one or more 
binary probes. Alternatively, the nucleic acid amplification 40 
and SNP gentotyping are carried out in a single reaction 
mixture, e.g., a combination of the first and second reaction 
mixtures. 
Primers 
For nucleic acid amplification of DNA from normal and 
cystic fibrosis patients, two sets of primers are used: (1) 
forward primer [5'-CAG AGA AAG ACA ATA TAG TTC 
C-3', SEQ IDNO. 3] and reverse primer [5'-AAA TGC TTG 
CTA GAC CAA T-3', SEQ ID NO. 4] for amplification ofa 
114bp fragment of the CFTR gene (de Araujo, Braz J Med 
Biol Res 38(1 ), 2005) and (2) random hexamer primers. 
Binary Probes 
For a binary DNA peroxidase probe specific for the G551 
D mutation (1652G>A) of the CFTR gene, two oligonucle-
otide strands are used: (1) 5'-1652 strand, of sequence [5'-
TGG AGA TCA AGG GTA GGG-3', SEQ ID NO. 5] con-
taining an 5'-analyte binding arm (10 nucleotides) and 
3'-hemin binding arm; and (2) 3'-WT strand, of sequence 
[5'-GGG TTG GGC GAG CAA GA-3', SEQ ID NO. 6] 
containing a 5'-hemin binding arm and 3'-analyte binding arm 
(9 nucleotides). For a binary DNA peroxidase probe specific 
for the corresponding wildtype sequence of the CFTR gene, 
two oligonucleotide strands are used: (1) 5'-WT strand, of 
sequence [5'-TGG AGG TCAAGG GTA GGG-3', SEQ ID 
NO. 7] containing an analyte binding arm (first 10 5'-nucle-The kit or apparatus, for example, can be provided which 
are configured to assist in executing the following steps: 45 otides) and hemin binding arm; and (2) 3'-WT strand. 
1) Providing a template nucleic acid to a first reaction 
mixture comprising reagents needed for isothermal 
nucleic acid amplification. 
2) Incubating the reaction mixture at room temperature for 
Xmin. 
3) Transferring part or all of the first reaction mixture to a 
second reaction mixture comprising binary DNA per-
oxidase probe, hemin, peroxidase substrate, and other 
reagents needed for SNP genotyping. 
4) Incubating the reaction mixture at room temperature for 
Ymin. 
5) Determining if the sequence or SNP is present by chemi-
luminescence or visible detection of the second reaction 
mixture. 
In one embodiment, the peroxidase substrate is luminal for 
chemiluminescence detection. In a preferred embodiment, 
the peroxidase substrate is DAB (3-3'-diaminobenzidine tet-
rahydrochloride) or ABTS (2,2'-azino-bis(3-ethylbenzthia-
zoline-6-sulphonic acid) or TMB (3,3',5,5'-tetramethylbenzi-
dine) for visual detection. 
Other features and advantages of the invention will be 
apparent from the following description of the preferred 
The two analyte binding arms of each oligonucleotide 
strand are selected with melting temperatures of 25-30° C., 
where the SNP of interest binds the middle of one analyte 
binding arm (e.g., compare sequence 5'-1652 and 5'-WT), and 
50 a SNP mismatch greatly reduces the melting temperature, 
resulting in probe unable to bind and assemble into an active 
form. For example, the melting temperature of strands 
5'-1652 and 3'-WT-with analyte DNA from cystic fibrosis 
patients with the G551D mutation-is 25.0° C. and 27.3° C. 
55 respectively-calculated using OligoAnalyzer 3.1 (Inte-
grated DNA Tecnologies, Coralville, Iowa), suitable for 
room-temperature hybridization. The melting temperature of 
the same strands, 5'-1652 and 3'-WT, with analyte DNA from 
normal patients with wild-type SNP is 2.4° C. and 27.3° C. 
60 respectively, the former not suitable for room-temperature 
hybridization, or probe assembly into an active form. 
65 
The two hemin binding arms of each oligonucleotide 
strand are selected following Kolpashchikov, JACS 
130:2934, 2008. 
A binary DNA peroxidase probe with oligonucleotide 
strands 5'-1652 and 3'-WT can be used to screen analyte 
DNA-and patients-for the G551D mutation of the CFTR 
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gene, which is associated with cystic fibrosis. A positive 
signal, for example, a color reaction resulting from peroxi-
dase-like activity, would indicate one chromosomal copy 
(heterozygote) or two chromosomal copies (homo zygote) of 
the mutant SNP sequence; and no color reaction would indi- 5 
cate two chromosomal copies of normal, wildtype SNP 
sequence. Using a second binary DNA peroxidase pro be with 
oligonucleotide strands 5'-WT and 3'-WT can distinguish 
heterozygotes and homozygotes for the mutant SNP 
sequence, where heterozygotes would give a positive signal 10 
stemming from their one chromosomal copy of wildtype SNP 
sequence, and homozygotes lacking wildtype SNP sequence 
would give a negative (no) signal. 
ing 1 µM binary probes (with strands 5'-1652 and 3'-WT, or 
strands 5'-WI and 3'-WT), 50 mM HEPES pH 7.4, 50 mM 
MgCl2 , 20 mM KC!, 120 mM NaCl, 0.03% Triton X-100, 1 % 
DMSO, hemin (125 nM), 1 mM H20 2 , and 1 mM DAB. 
Duplicate samples are prepared without addition of binary 
probes (negative control). The tubes are incubated for 30 
minutes at 25° C., then the tubes are photographed using an 
Olympus FE-170 digital camera ( 6 mega pixels). 
After 30 minutes, samples from normal patients amplified 
with specific primers and detected with the 5'-WT /3 '-WT 
binary probe are brown in color, as are samples from cystic 
fibrosis patients (with the G551D mutation) that are amplified 
with specific primers and detected with the 5'-1652/3'-WT 
binary probe. Negative controls, including samples of normal 
In the example, other binary DNA peroxidase probes spe-
15 
cific for other SNPs-from the CFTR gene or other genes-
can be added to the same reaction to simultaneously (or 
sequentially) to detect other SNPs in a multiplex-type assay. 
patients detected with 5'-1652/3'-WT probe, and cystic fibro-
sis patients detected with the 5'-WT/3'-WT probe, are almost 
clear in color. 
Reagents 
Oligonucleotides are custom-made by Integrated DNA 
Technologies, Inc. (Coralville, Iowa). Hydrogen peroxide, 
3-3'-diaminobenzidine tetrahydrochloride (DAB), 2,2'-
azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS), 




Two types of isothermal nucleic acid amplification steps 
are performed: (1) phi29 DNA polymerase (adapted from 
Dean et al. PNAS 99:5261, 2002); and (2) IsoAmpII Univer-
sal tHDA Kit (using helicase) ofBiohelix (Beverly, Mass.). 
A total ofl 2 samples of DNA-10 from normal patients, 1 
from cystic fibrosis patient homozygous for the GS 51 D muta-
tion, and 1 cystic fibrosis patient homozygous for the R553X 
mutation-are amplified with each type of nucleic acid 
amplification. 
For amplification using phi29 DNA polymerase, 200 ng of 
genomic DNA is added to a tube containing 3 7 mM Tris-HCI 
(pH 7.5), 50 mM KC!, 10 mM MgCl2 , 5 mM (NH4 ) 2 S04 , 1 
mM dNTPs, 50 pm forward primer, 50 pm reverse primer, 1 
U/ml yeast pyrophosphatase, and 800 U/ml phi29 DNA poly-
merase, and the tube is incubated at 25° C. for 1 hour. For 
random primer amplification, hexamer primers (final [30 
µMl) substitute forward and reverse primers. 
20 
Repeat genetic tests are performed using the same DNA 
amplification and SNP genotyping methodology, except the 1 
mM DAB (whose product is brown in color) in the SNP 
genotyping step was substituted with 1 mM ABTS (whose 
25 product is green in color). 
While various disclosed embodiments have been described 
above, it should be understood that they have been presented 
by way of example only, and not limitation. Numerous 
30 changes to the subject matter disclosed herein can be made in 
accordance with this Disclosure without departing from the 
spirit or scope of this Disclosure. In addition, while a particu-
lar feature may have been disclosed with respect to only one 
of several implementations, such feature may be combined 
35 with one or more other features of the other implementations 
as may be desired and advantageous for any given or particu-
lar application. 
Thus, the breadth and scope of the subject matter provided 
40 in this Disclosure should not be limited by any of the above 
explicitly described embodiments. Rather, the scope of this 
Disclosure should be defined in accordance with the follow-
ing claims and their equivalents. 
The terminology used herein is for the purpose of describ-
45 ing particular embodiments only and is not intended to be 
limiting. As used herein, the singular forms "a," "an," and 
"the" are intended to include the plural forms as well, unless 
the context clearly indicates otherwise. Furthermore, to the 
50 extent that the terms "including," "includes," "having," "has," 
"with," or variants thereof are used in either the detailed 
description and/or the claims, such terms are intended to be 
inclusive in a manner similar to the term "comprising." 
For amplification using tHDA and helicase, 200 ng of 
genomic DNA is added to a tube containing lx Amlealing 
Buffer, 4 mM MgS04 , 50 mM NaCl, 50 pm forward primer, 
50 pm reverse primer, IsoAmp dNTP, and IsoAmp Enzyme 
55 
Mix (as recommended by manufacturer), and the tube is 
incubate at 25° C. for 1 hour. For random primer amplifica-
tion, hexamer primers (final [30 µMl) substitute forward and 
Unless otherwise defined, all terms (including technical 
and scientific terms) used herein have the same meaning as 
commonly understood by one of ordinary skill in the art to 
which embodiments belong. It will be furtherunderstood that 
terms, such as those defined in commonly used dictionaries, 
60 
should be interpreted as having a meaning that is consistent 
with their meaning in the context of the relevant art and will 
not be interpreted in an idealized or overly formal sense 
unless expressly so defined herein. 
reverse primers. 
Example 3 
SNP Genotyping and Colormetric Assay 
For genotyping patient DNA ("the analyte"), 1h of the 
nucleic acid amplification reaction is added to a tube contain-
The teachings of any patents, patent applications, technical 
65 or scientific articles or other references are incorporated 
herein in their entirety to the extent not inconsistent with the 
teachings herein. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 7 
<210> SEQ ID NO 1 
<211> LENGTH, 12 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 1 
gggcgggttg gg 
<210> SEQ ID NO 2 
<211> LENGTH, 12 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 2 
gggcgggatg gg 
<210> SEQ ID NO 3 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 3 
cagagaaaga caatatagtt cc 
<210> SEQ ID NO 4 
<211> LENGTH, 18 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 4 
aaatgcttgc tagaccaa 
<210> SEQ ID NO 5 
<211> LENGTH, 18 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 5 
tggagatcaa gggtaggg 
<210> SEQ ID NO 6 
<211> LENGTH, 17 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<210> SEQ ID NO 7 
<211> LENGTH, 18 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 7 
tggaggtcaa gggtaggg 
What is claimed is: 
1. A method of detecting a sequence in a region of nucleic 
acid, comprising: 
i. amplifying the region of nucleic acid comprising said 
sequence using at least one oligonucleotide primer, and 
a primer hybridization temperature ofless than 37° C., 
wherein the amplifying is conducted without helicase; 
and 
ii. detecting said sequence in the amplified region of 
nucleic acid using at least one binary probe, wherein said 
binary probe comprises two separate oligonucleotide 
molecules each comprising a strand of 6-20 nucleotides 
that hybridize side by side to said sequence and when 
bound to said sequence interact to produce a detectable 
signal. 
2. The method of claim 1, wherein the sequence is l-to-12 
nucleotides in length. 
15 
18 
10. The method of claim 1, wherein the amplification of 
nucleic acid uses mesophilic or psychrophilic DNA poly-
merases. 
11. The method of claim 10, wherein the mesophilic DNA 
20 
polymerase is phi29 DNA polymerase. 
12. The method of claim 10, wherein the psychrophilic 
DNA polymerase is pike lymphosarcoma DNA polymerase. 
13. The method of claim 1, wherein the binary probe is a 
binary fluorimetric probe, a binary luminescence probe, or a 
binary colormetric probe. 
25 14. The method of claim 13, wherein the binary probe is a 
binary colormetric probe. 
15. The method of claim 13, wherein the binary probe is a 
binary DNA peroxidase probe. 
16. The method of claim 15, wherein the binary DNA 
30 peroxidase probe comprises a first and second oligonucle-
otide strand, wherein the first oligonucleotide strand com-
prises: 
3. The method of claim 2, wherein the sequence is 1 nucle-
otide in length. 
4. The method of claim 3, wherein the sequence is a single 
35 
nucleotide polymorphism. 
a) an analyte binding arm at the 5'-terminus, which is 
complementary to and hybridizes to a first region of the 
analyte, 
b) an optional linker, and 
c) a porphyrin binding arm at the 3'-terminus, and the 5. The method of claim 1, wherein the nucleic acid is RNA. 
6. The method of claim 5, wherein the RNA is ribosomal 
RNA. 
7. The method of claim 1, wherein the nucleic acid is DNA. 
40 
8. The method of claim 7, wherein the DNA is genomic 
DNA. 
9. The method of claim 1, wherein the primer hybridization 
temperature is 20° C-to-25° C. 
second oligonucleotide strand comprises: 
a) a porphyrin binding arm at the 5'-terminus, 
b) an optional linker, and 
c) an analyte binding arm at the 3'-terminus, which is 
complementary to and hybridizes to a first region of the 
analyte. 
* * * * * 
